Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

ASLS wins Frost & Sullivan bioprinting award

By Sean Whooley | January 9, 2020

Advanced Solutions Life Sciences announced that it won the Frost & Sullivan 2019 Bioprinting Value Leadership Award for demonstrating best-in-class biofabrication, hardware, software and consulting services.

Last month’s award highlights global consultancy firm Frost & Sullivan’s view that ASLS develops unique and cost-effective solutions to advance the development of life-saving drugs by way of 3D bioprinting, with emphasis on tissue engineering.

Louisville, Ky.–based ASLS produces the BioAssemblyBot, which it touts as the world’s only 3D bioprinter with a six-axis robotic arm to translate regenerative medicine therapies from benchtop to bedside.

“ASLS is an organization grounded in customer satisfaction & continuous improvement, delivering true value through their market-leading 3D bioprinters,” Frost & Sullivan senior research analyst in life sciences Aarti Chitale said in a news release. “It has developed an extensive ecosystem comprising of biofabrication, vascularization and machine learning software to support adjacent applications in research laboratories to biopharmaceutical factories. ASLS is drastically simplifying the tissue engineering workflow, while expanding experimental throughput by 20x in most cases.”

The 50-person company is looking to continue its growth with a strategic R&D and distribution partnership with GE Healthcare Life Sciences (NYSE:GE) centered around the goal of personalized tissue regeneration, which was announced last month.

Get the full story at our sister site, Medical Design & Outsourcing.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Novartis logo
Novartis mulls sale of $25 billion Sandoz generics arm
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Fujifilm Diosynth Technologies
Fujifilm to spend $1.6B to bolster cell culture manufacturing services
Zantac
First Zantac trial slated for February 2023

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards